LVW Advisors LLC Raises Position in Glaukos Co. (NYSE:GKOS)

LVW Advisors LLC boosted its holdings in Glaukos Co. (NYSE:GKOS) by 22.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,273 shares of the medical instruments supplier’s stock after purchasing an additional 413 shares during the period. LVW Advisors LLC’s holdings in Glaukos were worth $341,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Oak Ridge Investments LLC bought a new stake in shares of Glaukos in the 4th quarter valued at about $1,672,000. Harbor Capital Advisors Inc. purchased a new position in Glaukos in the 4th quarter worth approximately $3,679,000. GAMMA Investing LLC boosted its stake in shares of Glaukos by 28.3% during the fourth quarter. GAMMA Investing LLC now owns 2,213 shares of the medical instruments supplier’s stock valued at $332,000 after purchasing an additional 488 shares during the period. Exome Asset Management LLC purchased a new stake in shares of Glaukos during the third quarter valued at approximately $3,369,000. Finally, Franklin Resources Inc. grew its holdings in shares of Glaukos by 80.1% in the third quarter. Franklin Resources Inc. now owns 15,621 shares of the medical instruments supplier’s stock worth $2,031,000 after purchasing an additional 6,948 shares during the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 10,000 shares of Glaukos stock in a transaction on Friday, December 20th. The stock was sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the sale, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,859,454.08. This trade represents a 23.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Joseph E. Gilliam sold 3,328 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $149.85, for a total value of $498,700.80. Following the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $15,310,024.65. The trade was a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 17,603 shares of company stock valued at $2,605,678 in the last quarter. 6.40% of the stock is owned by insiders.

Glaukos Trading Up 0.1 %

NYSE:GKOS opened at $156.60 on Tuesday. Glaukos Co. has a one year low of $83.90 and a one year high of $161.13. The company’s 50-day simple moving average is $146.21 and its 200 day simple moving average is $133.86. The firm has a market capitalization of $8.63 billion, a P/E ratio of -51.85 and a beta of 1.04. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The company had revenue of $96.70 million for the quarter, compared to the consensus estimate of $91.50 million. During the same quarter in the prior year, the business posted ($0.50) EPS. The firm’s quarterly revenue was up 23.9% compared to the same quarter last year. As a group, analysts forecast that Glaukos Co. will post -1.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GKOS has been the subject of several analyst reports. BTIG Research increased their price target on shares of Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Wells Fargo & Company raised their target price on Glaukos from $145.00 to $153.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Citigroup raised Glaukos from a “neutral” rating to a “buy” rating and upped their price target for the company from $132.00 to $162.00 in a research report on Wednesday, December 11th. UBS Group assumed coverage on Glaukos in a research report on Friday, December 6th. They issued a “buy” rating and a $182.00 price objective on the stock. Finally, StockNews.com upgraded Glaukos from a “sell” rating to a “hold” rating in a report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus price target of $147.75.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.